ArticleThe Lancet. Oncology2016

Correction to Lancet Oncol 2016; 17: 248, 252. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.